Karen E Hayes
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$3.4MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $3.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 22, 2025 | NIH | SBIR Phase II Modulation of cancer induced immune suppression via inhibition of SCD1 | $218K | MODULATION THERAPEUTICS, INC. |
| Aug 30, 2024 | NIH | SBIR Phase II Modulation of cancer induced immune suppression via inhibition of SCD1 | $670K | MODULATION THERAPEUTICS, INC. |
| Aug 23, 2023 | NIH | SBIR Phase II Modulation of cancer induced immune suppression via inhibition of SCD1 | $1.3M | MODULATION THERAPEUTICS, INC. |
| Sep 15, 2022 | NIH | SBIR Phase II Modulation of cancer induced immune suppression via inhibition of SCD1 | $400K | MODULATION THERAPEUTICS, INC. |
| Aug 29, 2019 | NIH | SBIR Phase II Development of PEGylated MTI-101 for the treatment of relapsed Myeloma | $764K | MODULATION THERAPEUTICS, INC. |
Peer ranks
Federal funding#522
Awards as PI#417
Patents#273
Companies
- MODULATION THERAPEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.